Patent Cliff To Cause A Decline Drug Market Value

Despite a compound annual growth rate (CAGR) of 1.26% in local currency terms and 3.71% in US dollar terms from 2004-2009, BMI's outlook for the French drug market is less optimistic over the next five years. From 2009-2014, a CAGR of -1.41% is projected in local currency terms (-3.50% in US dollar terms), largely as a result of the impending patent cliff and the consequent consumption of lower-value generic drugs in place of the high-value patented drugs. BMI calculates that drug sales in France reached EUR30.25bn (US$42.61bn) in 2009. It is expected that 2010 drug sales will reach EUR30.49bn (US$42.94bn),

To read the full article, please choose one of the following options: